Key result
Remimazolam did not differ from target-controlled propofol in the maximum decrease of mean arterial pressure during induction of general anesthesia.
Why the study?
Remimazolam confers a lower risk of hypotension than propofol, but no studies have compared the efficacy of remimazolam and propofol administered using target-controlled infusion.
Does remimazolam improve hemodynamic stability compared to target-controlled propofol during induction of anesthesia in middle-aged and elderly adults?
RCT (n=40)
Single-blind
Sealed envelope system
No
Does remimazolam improve hemodynamic stability compared to target-controlled propofol during induction of anesthesia in middle-aged and elderly adults?
Remimazolam and target-controlled propofol result in similar hemodynamic changes during the induction of general anesthesia in middle-aged and elderly patients.
Answers are grounded in this paper and cite their sources.
Remimazolam shows no hemodynamic edge over TCI propofol here; leaves open whether larger trials would detect differences in hypotension risk.
BACKGROUND: Remimazolam confers a lower risk of hypotension than propofol. However, no studies have compared the efficacy of remimazolam and propofol administered using target-controlled infusion (TCI). This study aimed to investigate hemodynamic effects of remimazolam and target-controlled propofol in middle-aged and elderly patients during the induction of anesthesia. METHODS: Forty adults aged 45-80 years with the American Society of Anesthesiologists Physical Status 1-2 were randomly assigned to remimazolam or propofol group (n = 20 each). Patients received either remimazolam (12 mg/kg/h) or propofol (3 μg/mL, TCI), along with remifentanil for inducing anesthesia. We recorded the blood pressure, heart rate (HR), and estimated continuous cardiac output (esCCO) using the pulse wave transit time. The primary outcome was the maximum change in mean arterial pressure (MAP) after induction. Secondary outcomes included changes in HR, cardiac output (CO), and stroke volume (SV). RESULTS: MAP decreased after induction of anesthesia in both groups, without significant differences between the groups (- 41.1 [16.4] mmHg and - 42.8 [10.8] mmHg in remimazolam and propofol groups, respectively; mean difference: 1.7 [95% confidence interval: - 8.2 to 4.9]; p = 0.613). Furthermore, HR, CO, and SV decreased after induction in both groups, without significant differences between the groups. Remimazolam group had significantly shorter time until loss of consciousness than propofol group (1.7 [0.7] min and 3.5 [1.7] min, respectively; p < 0.001). However, MAP, HR, CO, and SV were not significantly different between the groups despite adjusting time until loss of consciousness as a covariate. Seven (35%) and 11 (55%) patients in the remimazolam and propofol groups, respectively, experienced hypotension (MAP < 65 mmHg over 2.5 min), without significant differences between the groups (p = 0.341). CONCLUSIONS: Hemodynamics were not significantly different between remimazolam and target-controlled propofol groups during induction of anesthesia. Thus, not only the choice but also the dose and usage of anesthetics are important for hemodynamic stability while inducing anesthesia. Clinicians should monitor hypotension while inducing anesthesia with remimazolam as well as propofol. TRIAL REGISTRATION: UMIN-CTR (UMIN000045612).
No takes yet. Share an insight, caveat, or question.
Sekiguchi et al. (2023) conducted an RCT in General anesthesia induction (n=40). Remimazolam vs. Target-controlled propofol (3 μg/mL) was evaluated on Maximum change in mean arterial pressure (MAP) after induction (MD 1.7, 95% CI -8.2 to 4.9, p=0.613). Remimazolam did not differ from target-controlled propofol in the maximum decrease of mean arterial pressure during induction of general anesthesia.
Synapse has enriched 10 related papers. Consider them for comparative context: